ABSTRACT
Background: Ischemic Stroke is a common cause of morbidity and mortality. Various parameters, both clinical and laboratory have been studied as markers of Early Neurological Deterioration (END) out of which CRP has been the most important. This retrospective study of ours is an attempt to study its influence on END by minimizing other variables as much as possible.Methods: 50 patients were chosen retrospectively strictly according to laid down inclusion and exclusion criteria, their data recorded and analyzed with 17.0 SPSS software. Any p value <0.05 was taken as significant.Results: Significantly raised CRP values were found in elderly patients (p=0.0001) and in males (p=0.003). Higher incidences of ENDs were also found in elderly patients (p=0.326) and males (p=0.846) and patients with raised CRP levels (p=0.057).Conclusions: Higher Values of CRP are associated with increased frequency of ENDs. But in patients with multiple factors which can influence both CRP and END, CRP alone should not be thought of as the only culprit.
ABSTRACT
Background: Diabetes mellitus (DM) is extremely common; represent a significant global health problem. Type-2 DM is considered to be associated with a low grade inflammation, which may play a significant role in development of cardiovascular complications evidenced by C-reactive protein (CRP) is a an extremely sensitive marker of systemic inflammation. The study was undertaken to check the effect of metformin on CRP level in Type-2 DM. Methods: The study was prospective and non-randomized. Thirty newly diagnosed Type-2 DM selected for metformin therapy by medicine personnel were enrolled in the study based on inclusion and exclusion criteria. Patients were divided into pretreatment (before starting metformin therapy) and post-treatment group. Fasting blood sugar (FBS), postprandial blood sugar (PP2BS), CRP level were measured at the time of enrolment and 3 months after starting metformin monotherapy. Results: Results were analyzed using pair t-test. Metformin therapy was found to decrease CRP level significantly along with FBS, PP2BS level. p<0.05 value considered as statistically significant. Value was expressed as mean ± standard deviation. Conclusions: Treatment with 3 months metformin monotherapy for newly diagnosed Type-2 DM has shown a significant decrease in high-sensitivity-CRP level in Type 2 diabetes. This positive effect may be because of the decreased in the expression of proinflammatory cytokines and other mediators, including adhesion molecules, suggests that these processes may contribute to atherogenesis because atherosclerosis is also an inflammatory condition. However, this effect is probably dependent on improving glycemic control.